Inhibrx shares surge after bone cancer drug slows disease progression in trial

Inhibrx shares surge after bone cancer drug slows disease progression in trial

(Reuters) -Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended trading. In the 206-patient study, the drug, ozekibart, extended the time patients lived without their cancer worsening to 5.52 months, compared with 2.66 months for those on placebo. Inhibrx continue reading...